Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Derrick Sung Biography and Net Worth

CFO of Pulmonx

Derrick brings to Pulmonx over 20 years of finance, strategy, and commercial experience across multiple facets of the medical device industry. Prior to joining Pulmonx, Derrick was Executive Vice President, Strategy & Corporate Development at iRhythm Technologies, Inc. (NASDAQ: IRTC), where he set strategic and financial direction for the company and helped guide iRhythm through a successful IPO. Prior to iRhythm, Derrick spent seven years on Wall Street as the senior equity research analyst covering the medical device sector for Sanford C. Bernstein & Company. Previously, Derrick was Director of Marketing and Business Development in Boston Scientific Corp.’s Neuromodulation Division; a management consultant at the Boston Consulting Group; and he started his career as an R&D engineer designing heart catheters for Guidant Corporation, now a part of Abbott Vascular. Derrick received his Ph.D. in Bioengineering from the University of California, San Diego; his MBA from San Diego State University, and his B.S. in Mechanical Engineering from Stanford University.

What is Derrick Sung's net worth?: The estimated net worth of Derrick Sung is at least $3.52 million as of September 1st, 2023. Dr. Sung owns 391,041 shares of Pulmonx stock worth more than $3,519,369 as of May 19th. This net worth evaluation does not reflect any other investments that Dr. Sung may own. Learn More about Derrick Sung's net worth.
How do I contact Derrick Sung?: The corporate mailing address for Dr. Sung and other Pulmonx executives is , , . Pulmonx can also be reached via phone at 1-650-364-0400 and via email at [email protected]. Learn More on Derrick Sung's contact information.
Has Derrick Sung been buying or selling shares of Pulmonx?: Derrick Sung has not been actively trading shares of Pulmonx over the course of the past ninety days. Most recently, Derrick Sung sold 4,219 shares of the business's stock in a transaction on Friday, September 1st. The shares were sold at an average price of $10.00, for a transaction totalling $42,190.00. Following the completion of the sale, the chief financial officer now directly owns 391,041 shares of the company's stock, valued at $3,910,410. Learn More on Derrick Sung's trading history.
Who are Pulmonx's active insiders?: Pulmonx's insider roster includes Daniel Florin (Director), Glendon French, III (CEO), David Lehman (General Counsel), Geoffrey Rose (Insider), and Derrick Sung (CFO). Learn More on Pulmonx's active insiders.
Are insiders buying or selling shares of Pulmonx?: In the last twelve months, insiders at the sold shares 30 times. They sold a total of 140,168 shares worth more than $1,636,984.34. The most recent insider tranaction occured on April, 22nd when insider Geoffrey Beran Rose sold 1,184 shares worth more than $8,868.16. Insiders at Pulmonx own 5.7% of the company. Learn More about insider trades at Pulmonx.
Information on this page was last updated on 4/22/2024.

Derrick Sung Insider Trading History at Pulmonx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/1/2023	Sell	4,219	$10.00	$42,190.00	391,041
6/1/2023	Sell	4,222	$11.49	$48,510.78	395,260
3/1/2023	Sell	1,264	$11.03	$13,941.92	261,482
12/14/2021	Sell	3,000	$32.89	$98,670.00
9/20/2021	Sell	3,000	$37.35	$112,050.00
9/1/2021	Sell	383	$40.09	$15,354.47	17,217
4/5/2021	Sell	5,000	$47.60	$238,000.00	223,879

Derrick Sung Buying and Selling Activity at Pulmonx

Pulmonx Company Overview

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Today's Range

Now: $9.00

$8.89

$9.09

50 Day Range

MA: $8.51

$7.28

$9.82

2 Week Range

Now: $9.00

$7.11

$14.84

Volume

170,400 shs

Average Volume

506,822 shs

Market Capitalization

$349.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66

Elon to Transform U.S. Economy?

From Porter & Company | Ad

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.